Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 85.0%

Neg 0% Neu 0% Pos 85%

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.